Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response

Por Kuwabara, Aya, Babb, Anna, Ibrahim, Amr, Milojkovic, Dragana, Apperley, Jane, Bua, Marco, Reid, Alistair, Foroni, Letizia, Rezvani, Katayoun, Goldman, John, Marin, David
Publicado em 2010

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients

Por Milojkovic, Dragana, Apperley, Jane F., Gerrard, Gareth, Ibrahim, Amr R., Szydlo, Richard, Bua, Marco, Reid, Alistair, Rezvani, Katayoun, Foroni, Letizia, Goldman, John, Marin, David
Publicado no Blood (2012)

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies

Por Neelakantan, Pratap, Gerrard, Gareth, Lucas, Claire, Milojkovic, Dragana, May, Philippa, Wang, Lihui, Paliompeis, Christos, Bua, Marco, Reid, Alistair, Rezvani, Katayoun, O'Brien, Stephen, Clark, Richard, Goldman, John, Marin, David
Publicado no Blood (2013)

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

Por Ibrahim, Amr R., Paliompeis, Christos, Bua, Marco, Milojkovic, Dragana, Szydlo, Richard, Khorashad, Jamshid S., Foroni, Letizia, Reid, Alistair, de Lavallade, Hugues, Rezvani, Katayoun, Dazzi, Francesco, Apperley, Jane F., Goldman, John M., Marin, David
Publicado no Blood (2010)

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

Por Marin, David, Milojkovic, Dragana, Olavarria, Eduardo, Khorashad, Jamshid S., de Lavallade, Hugues, Reid, Alistair G., Foroni, Letizia, Rezvani, Katayoun, Bua, Marco, Dazzi, Francesco, Pavlu, Jiri, Klammer, Matthias, Kaeda, Jaspal S., Goldman, John M., Apperley, Jane F.
Publicado no Blood (2008)

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Por Milojkovic, Dragana, Nicholson, Emma, Apperley, Jane F., Holyoake, Tessa L., Shepherd, Pat, Drummond, Mark W., Szydlo, Richard, Bua, Marco, Foroni, Letizia, Reid, Alistair, Khorashad, Jamshid S., de Lavallade, Hugues, Rezvani, Katy, Paliompeis, Christos, Goldman, John M., Marin, David
Publicado em 2010

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibito...

Por Marin, David, Ibrahim, Amr R., Lucas, Claire, Gerrard, Gareth, Wang, Lihui, Szydlo, Richard M., Clark, Richard E., Apperley, Jane F., Milojkovic, Dragana, Bua, Marco, Pavlu, Jiri, Paliompeis, Christos, Reid, Alistair, Rezvani, Katayoun, Goldman, John M., Foroni, Letizia
Publicado no J Clin Oncol (2012)

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

Por Ibrahim, Amr R., Eliasson, Lina, Apperley, Jane F., Milojkovic, Dragana, Bua, Marco, Szydlo, Richard, Mahon, Francois-Xavier, Kozlowski, Kasia, Paliompeis, Christos, Foroni, Letizia, Khorashad, Jamshid S., Bazeos, Alex, Molimard, Mathieu, Reid, Alistair, Rezvani, Katayoun, Gerrard, Gareth, Goldman, John, Marin, David
Publicado no Blood (2011)

Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma

Por Gabriel, Ian H., Sergeant, Ruhena, Szydlo, Richard, Apperley, Jane F., deLavallade, Hugues, Alsuliman, Abdullah, Khoder, Ahmad, Marin, David, Kanfer, Edward, Cooper, Nichola, Davis, John, MacDonald, Donald, Bua, Marco, Foroni, Letizia, Giles, Chrissy, Milojkovic, Dragana, Rahemtulla, Amin, Rezvani, Katayoun
Publicado no Blood (2010)

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

Por Marin, David, Bazeos, Alexandra, Mahon, Francois-Xavier, Eliasson, Lina, Milojkovic, Dragana, Bua, Marco, Apperley, Jane F., Szydlo, Richard, Desai, Ritti, Kozlowski, Kasia, Paliompeis, Christos, Latham, Victoria, Foroni, Letizia, Molimard, Mathieu, Reid, Alistair, Rezvani, Katy, de Lavallade, Hugues, Guallar, Cristina, Goldman, John, Khorashad, Jamshid S.
Publicado no J Clin Oncol (2010)

Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors

Por Tornatore, Laura, Sandomenico, Annamaria, Raimondo, Domenico, Low, Caroline, Rocci, Alberto, Tralau-Stewart, Cathy, Capece, Daria, D’Andrea, Daniel, Bua, Marco, Boyle, Eileen, van Duin, Mark, Zoppoli, Pietro, Jaxa-Chamiec, Albert, Thotakura, Anil K., Dyson, Julian, Walker, Brian A., Leonardi, Antonio, Chambery, Angela, Driessen, Christoph, Sonneveld, Pieter, Morgan, Gareth, Palumbo, Antonio, Tramontano, Anna, Rahemtulla, Amin, Ruvo, Menotti, Franzoso, Guido
Publicado em 2014

Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors

Por Tornatore, Laura, Sandomenico, Annamaria, Raimondo, Domenico, Low, Caroline, Rocci, Alberto, Tralau-Stewart, Cathy, Capece, Daria, D’Andrea, Daniel, Bua, Marco, Boyle, Eileen, van Duin, Mark, Zoppoli, Pietro, Jaxa-Chamiec, Albert, Thotakura, Anil K., Dyson, Julian, Walker, Brian A., Leonardi, Antonio, Chambery, Angela, Driessen, Christoph, Sonneveld, Pieter, Morgan, Gareth, Palumbo, Antonio, Tramontano, Anna, Rahemtulla, Amin, Ruvo, Menotti, Franzoso, Guido
Publicado no Cancer Cell (2014)